CompletedNot Applicable

Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01)

Canada1 participantsStarted 2024-01-16

Plain-language summary

Single-patient trial aiming to provide immunological consolidation following allogeneic stem cell transplantation to a young adult patient suffering from a systemic EBV-positive lymphoma of childhood.

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Capacity to provide informed consent
✓. Age ≥ 18
✓. Negative serum pregnancy test and use of effective contraception method.

Exclusion criteria

✕. Administration within less than 28 days of T-cell depleting antibodies (ATG, OKT3, Campath)
✕. Pregnancy
✕. Any abnormal condition or laboratory result that is considered by the Principal Investigator capable of altering patient or study outcome.
✕. Active uncontrolled GVHD (acute GVHD grade II-IV or progressive extensive chronic GVHD) at time of enrolment or infusion.

What they're measuring

Safety of a donor-derived EBV-specific T-cell line as assessed clinically by the lack of graft-versus-host host (GVHD).

Timeframe: 1 year

Trial details

NCT IDNCT06391814

SponsorCiusss de L'Est de l'Île de Montréal

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-04-05

View on ClinicalTrials.gov More EBV Associated Lymphoma trials